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CBT.Conclusion:These results strongly suggested that unrelated
CBT could be safely used for adult patients with hematological
malignancies.
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Uncertainty still exists with the effects of allogeneic PBSCT on
the clinical outcomes of patients with hematological malignancies.
Our aim was analyzed retrospectively the clinical outcomes of 483
patients who underwent an allo PBSCT in 9 Brazilian centers from
May 1994 to February 2004. The analyses included patients with
hematological malignancies who underwent PBSCT from HLA
identical sibling donors. Median age was 34 (2–57), advanced
disease was present in 58%, conditioning without irradiation was
85%; GVHD prophylaxis with MTX/CsA was 91%; CD34 me-
dian was 4.7  106/kg (0.51–71.6); the median follow-up for
surviving patients was 797 days (8–3420); median day for neutro-
phils and platelets engraftment was 15 and 14, respectively; cumu-
lative incidence (CI) for 3 2 aGVHD was 38%; extensive cGVHD
63%; CI for transplant relate mortality (TRM) 59%; CI for relapse
37%; the estimates of OS and DFS at 9 ys are 33% and 42%,
respectively. In univariate analyses the following factors were as-
sociated with better outcome: for neutrophils and platelets engraft-
ment- CD34 cell dose 2.8 106/kg, GVHD prophylaxis other
than MTX/CsA, and sex match other than female donor for male
recipient; aGVHD- age 
43, and CD34 dose 4.7  106/kg;
cGVHD- age 
25 ys, sex match other than female donor for male
recipient, advanced disease and CD3 dose 
170  106/kg; OS-
early disease; DFS- early disease, and CD34 dose 4.7  106/kg;
relapse- age 25 ys, CD34 cell dose 2.8  106/kg, and early
disease; TRM- early disease. All the results remained signiﬁcant in
multivariate analyses, but for CD34 dose and platelet engraft-
ment; age and CD34 dose in aGVHD; age and CD3 in
cGVHD, and age in relapse. In our experience, sex match, CD34
dose, GVHD prophylaxis may inﬂuence the engraftment, and sex
match and disease phase the cGVHD. Furthermore, advanced
disease had a negative impact on OS and TRM. CD34 higher
dose and early disease were associated with better DFS and lower
relapse.
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FLUDARABINE-BASED CONDITIONING SECURES ENGRAFTMENT OF
SECONDARY HEMATOPOIETIC STEM CELL ALLOGRAFTS (HSCT) USED
TO TREAT GRAFT FAILURE
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S.E.1; Small, T.N.1; Vandenbrink, M.R.M.2; Young, J.W.2; O’Reilly,
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Graft failure is associated with a high mortality rate. To date,
regimens invoked for secondary transplants have resulted in incon-
sistent engraftment with high transplant-related mortality. We
here report 15 patients, aged 4–59 years (median 24 years), who
received secondary HSCT (HSCT-2) following rejection of pri-
mary unmodiﬁed (N4) or T-cell depleted (N11) HSCT
(HSCT-1). HSCT-1 included myeloablative TBI- or alkylator-
based conditioning for acute leukemias (N5), MDS (N6), CML
(N3), and Fanconi anemia (N1). Cytoreduction regimens used
for HSCT-2 included: Fludarabine (Flu) alone (N2) or in com-
bination with Cyclophosphamide (CTX) (N8) or Thiotepa
(Thio) (N4), or Thio combined with CTX (N1). ATG (N11)
or Alemtuzumab (N3) was added pretransplant to prevent rejec-
tion. For HSCT-2, donors included: HLA-matched (N3) or
non-identical (N7) relatives and matched (N1) or non-identical
(N4) unrelated donors. The primary graft donor was used in
seven of ﬁfteen cases. The grafts administered were unmodiﬁed
PBSCT (N6) or BMT (N2) or T-cell depleted (TCD) PBSCT
(N7). Of 15 patients, 14 achieved engraftment with complete
chimerism. Mean time to engraftment (ANC 1000 for 3 days)
was 15.4 days. Seven patients died of infection (N5), graft failure
(N1), or encephalopathy (N1) within 100 days post-transplant,
and four patients succumbed to GVHD (N1), relapse (N1),
pneumonia (N1), or EBV lymphoma (N1) 6–15 months post-
transplant. Four patients are alive and disease-free with a median
follow-up of 51 months, including 3/8 conditioned with Flu/CTX.
In this limited series, younger patients (4/7
 20 years vs. 0/8 20
years), transplants from secondary donors (3/8 with secondary
donor vs. 1/7 with primary donor), and TCD HSCT-2 (3/7 TCD
vs. 1/8 unmodiﬁed) had a better outcome. In summary, secondary
HSCT following a Flu/ATG-based non-myeloablative regimen
have achieved consistent engraftment with hematopoietic recon-
stitution in patients with a primary graft failure, but are limited by
infections complicating delayed immune reconstitution.
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For patients (pts) with Non-Hodgkin’s Lymphoma (NHL), the
optimal timing and conditioning regimen intensity for transplant
has not been deﬁned. Nonmyeloablative stem cell transplants
(NMT) have been reserved for those patients at high risk for
treatment related morbidity and mortality (TRM) from conven-
tional High Dose allogeneic SCT (HDT) and have been increas-
ingly employed as salvage therapy for relapse after autotransplan-
tation. To assess the effectiveness of this approach, we performed
a retrospective analysis of 35 pts who have undergone either HDT
(n20) with a TBI-based regimen or NMT (n15) with a ﬂudara-
bine-based regimen followed by allogeneic SCT for high risk
NHL. Stem cell source varied by conditioning; 13/15 of HDT pts
received bone marrow (11 sib, 2 MUD), while all NMT pts
received peripheral blood (11 sib, 9 MUD). NMT pts constituted
a higher risk cohort based on extent of prior therapy (including
80% s/p autotransplant), chemoresistance, and age. Distribution of
histology for the entire group was skewed toward aggressive his-
tology, but equally distributed between HDT and NMT. For pts
surviving 90 days, median follow up for HDT pts is 50 months
(4–92 m), vs 12 months (4–45 m) for NMT pts. A comparison of
overall survival (53 vs 45%), event-free survival (53 vs 48%), and
progression-free survival (88 vs 64%) at 1 year demonstrated no
signiﬁcant differences between HDT and NMT cohorts despite
the higher risk nature of the NMT group. The 100-day TRM for
HDT vs NMT pts was similar (33 vs 30%, pns). The incidence
of grade II-IV acute GvHD was not signiﬁcantly different between
HDT (3/13 evaluable, 23%) and NMT (7/20, 35%). Among evalu-
able pts, chronic GvHD was lower in the HDT group vs NMT (13
vs 50%). Among causes of death, disease-related deaths were lower
in the HDT group (1/7, 14%) compared with NMT pts (5/11,
45%). This retrospective analysis demonstrates 1) NMT induces
durable remissions in a signiﬁcant number of poor risk pts; 2)
outcomes after NMT may be comparable to HDT; 3) relapse rates
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are higher after NMT while TRM is higher after HDT; and 4)
long term remissions suggest that NMT is associated with an
important graft vs lymphoma effect.
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STABLE LONG TERM ENGRAFTMENT AND AMELIORATION OF CLINICAL
PHENOTYPE FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION FROM A MATCHED SIBLING DONOR FOR SICKLE CELL DISEASE
USING A REDUCED INTENSITY CONDITIONING REGIMEN
Krishnamurti, L.1; Wu, C.2; Baker, S.3; Yeager, A.M.4; Wagner, J.E.3
1. Children’s Hospital of Pittsburgh, Pittsburgh, PA; 2. Dana Farber
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Hematopoietic stem cell transplantation (HCT) from sibling
donors has been demonstrated to cure hemoglobinopathies such as
sickle cell disease (SCD) and Thalassemia. Concerns about high
regimen related toxicity (RRT) have prevented the use of HCT in
older patients, those with advanced organ damage or those without
a HLA matched related donor. Also, potential for late sequelae
such as chronic graft-versus-host disease (GVHD) and infertility
have limited the acceptance of this treatment even by eligible
patients. HCT following a reduced intensity conditioning (RIC)
regimen has the potential for reducing toxicity and potentially
making this curative therapy more acceptable and applicable to this
group of patients. We initiated a pilot study to evaluate the safety
and efﬁcacy of HCT following a RIC regimen for patients with
high risk hemoglobinopathies. We report stable long term engraft-
ment with amelioration of clinical phenotype in the ﬁrst three
patients with SCD receiving HCT (unmodiﬁed bone marrow)
from a matched sibling donor, on this study. The conditioning
regimen consisted of Busulfan 2 mg/kg orally q 12 hr 2 days (0.8
mg/kg IV q 6 hr  2 days for patient #3), Fludarabine 35 mg/m2/
dose IV daily  5 days, antithymocyte globulin 30 mg/kg/dose IV
daily  5 days and total lymphoid irradiation administered as a
single fraction of 500 cGy with shielding of the liver, lungs, heart,
and gonads. Prophylaxis for GVHD consisted of cyclosporine A
and Mycophenolate mofetil. Clinical characteristics of the patients
and outcomes are summarized in Table 1. The preparative regi-
men was well tolerated with no serious infections or mucositis in
any patient. Nadir of absolute neutrophil count was 140–200 
109/L. Nadir of platelet count was 25–40  109/L. Transfusion
requirements were modest (3 PRBC and 3–5 platelet transfusions).
All patients are off immunosuppressive medications. Recovery of
splenic function was observed except in patient #2 had who had
prior splenectomy. No patient has had any recurrence of previous
sickle cell related symptoms such as stroke, pain crisis, priapism or
acute chest syndrome. End-organ changes are stable in all patients.
Lineage-speciﬁc chimerism analysis (patient #3) suggest predomi-
nance of donor erythropoiesis. These ﬁndings indicate that HCT
for sickle cell disease following a RIC regimen is well tolerated and
can lead to stable long term engraftment with amelioration of
clinical phenotype and stabilization of end- organ damage.
Clinical Characteristics of Patients With Sickle Cell Disease
Undergoing HCT From a Matched Sibling Donor Following a
Reduced Intensity Conditioning Regimen
PIN;
Indication
for HCT,
Age (Years)
Follow-
up
(Years)
Organ
Toxicity
Duration
of ANC
<500
(Days)
GVHD
Acute/
Chronic
Engraft-
ment %
Donor
(Bone
Marrow)
d  30
Engraft-
ment %
Donor
(Bone
Marrow)
d  100
Engraft-
ment %
Donor
(Bone
Marrow)
d  365
1. Stroke,
allosensi-
tization
8 yrs.
4 None 7 Nil 89 100 100
2. Repeated
ACS, 8
yrs.
3 None 8 Grade
II Skin
75 81 81
3. Repeated
ACS, 6
yrs.
1 None 9 Nil 75 85 81
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INTRAVENOUS BUSULFAN DOSED FOUR TIMES DAILY OR ONCE DAILY
AS PART OF THE STANDARD BUCY PREPARATIVE REGIMEN FOR AL-
LOGENEIC STEM CELL TRANSPLANTATION
Shaughnessy, P.J.; Bachier, C.; Alexander, L.; Bowen, B.; LeMaistre,
C.F. Texas Transplant Institute, San Antonio, TX.
Intravenous busulfan (IVBu) (Busulfex ESP Pharma) is now
regularly substituted for oral busulfan as part of the standard
busulfan and cyclophosphamide (BuCy) preparative regimen for
allogeneic stem cell transplantation (ASCT). Oral busulfan was
originally dosed 4 times daily, which led to the current accepted
dosing schedule for IVBu. Pharmacokinetics (PK) and busulfan
clearance allow for once daily dosing now that IVBu is available.
We performed a retrospective review of 36 consecutive patients
who received the BuCy preparative regimen with IVBu prior to
ASCT. Twenty-one males and 15 females with a median age of 46
years (23–64) were treated for AML (n15), ALL (n1), CML
(n8), MDS (n8), NHL (n2), and multiple myeloma (n2).
IVBu was dosed 0.8 mg/kg 4 times daily for 16 doses (n16) or 3.2
mg/kg once daily for 4 doses (n20) on days 7 to 4, and
cyclophosphamide was dosed 60 mg/kg once daily for two doses on
days 3 and 2. IVBu was dosed by ideal or adjusted ideal body
weight and no PK studies were done. Bone marrow (n6) or
peripheral blood (n30) stem cells were infused on day 0 from
HLA matched siblings (n26) or unrelated donors (n9), and one
partially matched unrelated donor. Engraftment occurred in 34
patients (pts) (94%). Two pts who failed to engraft had bone
marrow grafts with low numbers of total mononuclear cells in-
fused. Regimen related toxicity (RRT) included mild VOD in 2 pts
(5%) that self resolved, with one pt receiving IVBu 4 times daily
and the other once daily. There was no seizure activity or non-
infectious interstitial pneumonitis attributed to RRT in any pa-
tient. Other RRT were not signiﬁcantly different between the
patients who received 4 times daily or once daily IVBu. Day 100
mortality was 17%, and at a median follow up of 12 months (1–54)
17 pts (47%) survive. Five of 16 pts (31%) survive who received 4
times daily IVBu, and 12 of 20 pts (60%) survive who received once
daily IVBu, however, most patients who received once daily IVBu
were treated more recently. Three patients received once daily
IVBu as outpatients. In conclusion, this small retrospective single
institution study revealed IVBu dosed once daily by ideal or ad-
justed ideal body weight appeared to have similar RRT, engraft-
ment, and survival compared to 4 times daily IVBu when used as
part of the BuCy preparative regimen for ASCT.
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HIGH RELAPSE RATE FOLLOWING ALEMTUZAMAB USE IN ALLOGENEIC
TRANSPLANTS FOR MYELOID HEMATOLOGIC MALIGNANCIES
Shea, T.C.1; Serody, J.1; Gabriel, D.1; Comeauu, T.1; Morris, D.2;
Irons, R.1; Harvey, D.3; Sharf, A.1; Krasnov, C.1; Dunphy, C.4; Ban-
derenko, N.4; Brecher, M.4 1. Department of Medicine, Bone Marrow
and Stem Cell Transplant Program; 2. Department of Radiation On-
cology; 3. Department of Pharmacy; 4. Department of Pathology and
Laboratory Medicine, UNC Hospitals, Lineberger Comprehensive Can-
cer Center and School of Medicine, Chapel Hill, NC.
Chakravarti (Blood, ‘02, p 1071) and others have described the
use of alemtuzamab in vivo for control of graft vs host disease in
allotransplantation. Control of GVHD has been good, but high
relapse rates and infectious complications have been reported. We
describe 47 pts, 16 women and 31 men, median age 49, and median
f/u 11 months who underwent matched related (31) or unrelated
(16) bone marrow (8), blood stem cell (38), or both (1), transplants
for hematologic malignancies. All AML pts had high-risk disease
deﬁned as beyond CR1 (11), CR1 with high risk cytogenetics (5),
AML with dysplasia (12), or failed prior autolograft (1). Three had
10% marrow blasts at time of transplant. All other pts had
multiply recurrent disease. All pts received Alemtuzamab at 20
mg/d  5 (17), 30 mg/d  3 (25) or lower doses (5) between days
8 through 4, followed by tacrolimus. Conditioning regimens
included 12.8 mg/kg IV busulfan, (27), 6.4 mg/kg IV busulfan (9),
melphalan 140 mg/m2 (6), or Cy/TBI (1). All non-TBI patients
received 30 mg/m2/d  5 of ﬂudarabine. Median recovery of ANC
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